Clinical Trials | December 28, 2021
RaphaCure partners with Zeebon for foraying into North East market
Zeebon is the largest diagnostics services provider in North-Eastern states
Zeebon is the largest diagnostics services provider in North-Eastern states
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
2022 is going to be the year of opportunities and innovations from the medical industry in India
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Effectiveness of Covaxin against the Omicron variant is currently being studied
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
The company will manufacture a cancer immunotherapy product from 2022
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Subscribe To Our Newsletter & Stay Updated
